Our results suggest that the timing of radiotherapy and mutations of ROBO1 and KAT2B are potential indicators of PCNSL outcomes and may be affected by baseline characteristics such as age and sex. The gene discussed is KAT2B; the disease is primary central nervous system lymphoma.